Discounted Cash Flow Rating

Sell

Return on Equity Rating

Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Neutral

Simple Moving Average

Strong Sell

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

Intra-Cellular Therapies Inc. (ITCI)

Pharmaceutical Preparations

https://www.intracellulartherapies.com

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

430 EAST 29TH STREET
NEW YORK, NY

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

12/19/2013

Market Cap

7,930,308,350

Shares Outstanding

96,240,000

Weighted SO

96,238,126

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

ALKS --.--%

IRWD --.--%

DCPH --.--%

PCRX --.--%

COLL --.--%

EGRX --.--%

NBIX --.--%

DVAX --.--%

AMPH --.--%

Beta

1.0060

Last Div

0.0000

Range

45.5-84.89

Chg

-0.2200

Avg Vol

1103885

Mkt Cap

7930308350

Exch

NASDAQ

Country

US

Phone

646 440 9333

DCF Diff

69.9933

DCF

-1.6133

Div Yield

0.0000

P/S

14.0716

EV Multiple

-64.7909

P/FV

6.8009

Div Yield %

0.0000

P/E

-92.3374

PEG

-1.9933

Payout

0.0000

Current Ratio

7.8149

Quick Ratio

7.6907

Cash Ratio

4.2964

DSO

94.3727

DIO

178.4089

Op Cycle

272.7816

DPO

155.8968

CCC

116.8848

Gross Margin

0.9271

Op Margin

-0.1996

Pretax Margin

-0.1480

Net Margin

-0.1496

Eff Tax Rate

-0.0109

ROA

-0.0638

ROE

-0.1148

ROCE

-0.0971

NI/EBT

1.0109

EBT/EBIT

0.7414

EBIT/Rev

-0.1996

Debt Ratio

0.0138

D/E

0.0160

LT Debt/Cap

0.0122

Total Debt/Cap

0.0157

Int Coverage

-25.8646

CF/Debt

-3.3303

Equity Multi

1.1537

Rec Turnover

3.8676

Pay Turnover

2.3413

Inv Turnover

2.0459

FA Turnover

35.3291

Asset Turnover

0.4268

OCF/Share

-0.5872

FCF/Share

-0.5903

Cash/Share

9.8788

OCF/Sales

-0.1081

FCF/OCF

1.0053

CF Coverage

-3.3303

ST Coverage

-14.6020

CapEx Coverage

-189.1460

Div&CapEx Cov

-189.1460

P/BV

6.8009

P/B

6.8009

P/S

14.0716

P/E

-92.3374

P/FCF

-129.5231

P/OCF

-127.8124

P/CF

-127.8124

PEG

-1.9933

P/S

14.0716

EV Multiple

-64.7909

P/FV

6.8009

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 16, 23:15 $HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger – CCNE, ITCI, ENFN, AMPY GlobeNewswire Inc. Jan 14, 02:20 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN, ITCI, EDBL on Behalf of Shareholders Benzinga Jan 18, 09:00 Analyst Scoreboard: 8 Ratings For Intra-Cellular Therapies Benzinga Jan 02, 13:01 In-Depth Examination Of 6 Analyst Recommendations For Intra-Cellular Therapies Zacks Investment Research Jan 01, 09:55 Intra-Cellular Therapies (ITCI) Now Trades Above Golden Cross: Time to Buy? GlobeNewswire Inc. Nov 02, 07:30 Intra-Cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance

Revenue Product Segmentation